NCT01435408进行中（未招募）不适用
A Randomised Comparison of the Clinical Outcome After Postconditioning or Deferred Stent Implantation Versus Conventional Treatment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
- 试验地点
- 10
- 主要终点
- All cause mortality, heart failure (postconditioning)
研究概览
简要总结
This study focuses on Cardioprotective strategies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Acute onset of chest pain of < 12 hours' duration.
- •ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block.
- •Culprit lesion in a major native vessel.
排除标准
- •Pregnancy.
- •Known intolerance of ASA, clopidogrel, heparin or contrast.
- •Inability to understand information or to provide informed consent.
- •Haemorrhagic diathesis or known coagulopathy.
- •Stent thrombosis.
结局指标
主要结局
All cause mortality, heart failure (postconditioning)
时间窗: 2 years
次要结局
- All cause mortality, myocardial infarction, repeat revascularisation and occurrence of definite stent thrombosis according to ARC definition within 1 year (deferred stent strategy)(1 year)
- Infarct size in relation to area at risk as determined by MRI after 3 month(3 month)
研究者
Thomas Engstrom
MD, DMSci, PhD
Rigshospitalet, Denmark
研究点 (10)
Loading locations...
相似试验
已完成
4 期
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk FactorsHypertensionHypercholesterolemiaNCT00407537Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,531
已完成
不适用
A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failureHyperuricemia in patients with chronic heart failureJPRN-C000000426ational Cardiovascular Center213
已完成
不适用
Evaluation of Cardiovascular Health Outcomes Among SurvivorsCardiovascular RiskCancerNCT01003574St. Jude Children's Research Hospital509
已完成
不适用
Efficacy of intracoronary abciximab in percutaneous coronary interventioST-segment elevation myocardial infarction.myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onsetIRCT2012081310573N1Cardiovascular Research Center, Shahid Beheshti University of Medical sciences40
尚未招募
3 期
A COMPARASON OF EFFECTS OF KETAMINE-DEXMEDETOMIDINEVERSUS FENTANYL-PROPOFOL IN PATIENTS UNDERGOING CARDIACSURGERY FOR MYOCARDIAL PROTECTIOCTRI/2024/07/071613SMS Medical College and Hospital